W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

catenin beta 1

catenin beta 1

Overview

Catenin beta 1 (CTNNB1) encodes β-catenin, a multifunctional protein that is central to Wnt/β-catenin signaling and to cell–cell adhesion through cadherin-associated complexes. In the nucleus, β-catenin acts as a transcriptional co-regulator, influencing gene expression programs involved in development, tissue homeostasis, proliferation, and differentiation. Because of these roles, CTNNB1 is frequently studied in cancer biology, fibromatosis, and metabolic disease.

Clinically and experimentally, altered β-catenin localization or CTNNB1 mutation is often used as a marker of pathway activation. In pathology, nuclear β-catenin positivity can support diagnoses associated with Wnt pathway dysregulation, while in translational research CTNNB1 is also examined as a candidate target or biomarker in conditions such as type 2 diabetes, acute liver injury, and fibromatosis. Its interactions with other signaling nodes, including ESR1, TP53, and the JAK2/STAT3 signaling pathway, are also of interest in network-based and mechanistic studies.

Focus of Latest Publications

Recent publications have continued to use CTNNB1 as both a diagnostic molecular marker and a candidate disease-associated gene.

In a case report of complicated intra-abdominal fibromatosis masked by perforated jejunal diverticulitis (PMID: 42082267), immunohistochemistry showed positive β-catenin, and subsequent molecular analysis confirmed a CTNNB1 gene mutation. This finding supported the diagnosis of fibromatosis, consistent with the known association between CTNNB1 alterations and desmoid-type fibromatosis. The report illustrates how β-catenin immunostaining and CTNNB1 genotyping can complement surgical and histopathologic assessment in difficult abdominal lesions.

In a dermatopathology study of onychopapilloma (PMID: 42012242), the authors evaluated several onychogenic markers, including LEF-1 and beta-catenin, and reported that these markers were not expressed in the nail bed. This negative immunophenotype was part of a broader clinical and histological analysis of 56 cases and contributed to the characterization of onychopapilloma as a nail bed onycholemmal papilloma rather than a lesion showing the expected onychogenic marker profile.

A separate study focused on CTNNB1 genetic variation and its interaction with DLK1 in type 2 diabetes mellitus (PMID: 41961207). The authors reported that the CTNNB1 gene exhibits differential expression in T2DM, and that its genetic polymorphisms are associated with the disease. The study specifically investigated CTNNB1 polymorphisms and interacting molecules, placing the gene in the context of metabolic regulation and disease susceptibility. This work aligns with broader interest in Wnt/β-catenin signaling in metabolic disorders and suggests that CTNNB1 may contribute to the molecular architecture of T2DM.

In another network pharmacology analysis of acute liver injury (PMID: 42007886), CTNNB1 was identified as one of four hub genes alongside JUN, STAT3, and ESR1. The study integrated active monomers and pathway-based target prediction to prioritize core targets implicated in liver injury mechanisms. Although the publication context provided here does not specify a direct functional validation of CTNNB1, its identification as a hub gene suggests that β-catenin-related signaling may be part of the broader molecular response network in hepatic injury.

Taken together, these studies show CTNNB1 being used in several distinct ways: as a confirmatory marker of fibromatosis, as a negative/phenotypic comparator in nail-bed pathology, as a genetic association candidate in type 2 diabetes, and as a network-derived hub gene in acute liver injury. Across these contexts, the recurring biological theme is the involvement of β-catenin in transcriptional regulation, tissue remodeling, and disease-associated signaling networks, including pathways that intersect with Wnt/β-catenin pathway, JAK2/STAT3 signaling pathway, ESR1, and TP53.

Key Publications

Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.